• Username (E-mail)
  • Password
Dow 20,822 0.1%  EStoxx50 3,304 -0.9%  Nikkei 19,284 -0.5%  EUR 1.0565 0.0% 
Nasdaq 5,845 0.2%  FTSE100 7,244 -0.4%  Yen 112.1450 0.0%  Oil 56.0 -0.8% 
S&P500 2,367 0.2%  DAX 11,804 -1.2%  GBP 1.2484 0.2%  Gold 1,257 0.0% 

Celgene share [Symbol: CELG / ISIN: US1510201049]

Realtimequote Celgene Corp. in USD

Exchange Market
118.26
Last
402,304
Volume
Time 03:59 PM
02/24/2017 03:59:59 PM UTC-0500
activate push

Stock Price Celgene Corp. in USD

Activate push
118.23 USD -1.23 USD -1.03 %
Trade Time 8:10 PM Trade Date 2/24/2017
Daily High 0.00 Open 0.00
Daily Low 0.00 Prev. Close 118.23
52-week High 127.00 Volume (Qty.) 0
52-week Low 94.40 Market Cap (USD) 91.31 B
52-week Perf.
Exchange

Analyst Opinions for Celgene Corp.

More Analyst Opinions
  • All
  • Buy
  • Hold
  • Sell
01/08/13
Celgene Stifel, Nicolaus & Co., Inc.
01/08/13
Celgene RBC Capital Markets
01/04/13
Celgene RBC Capital Markets
01/02/13
Celgene RBC Capital Markets
12/14/12
Celgene Goldman Sachs Group Inc.

Moody's Rating for Celgene Corp.

Investment Grade (High Grade)
Investment Grade (Medium Grade)
Speculative Grade
Rating Baa2
Rating Update DNG
Date of Rating 8/3/2015
Rating Office USA

Profile Celgene Corp.

Company Profile
Celgene Corp. is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. Its targeting areas include intracellular signaling pathways, protein homeostasis and epigenetics in cancer and immune cells, immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies. The company's products include Revlimid, Vidaza, Thalomid, Pomalyst/Imnovid, Abraxane, and Istodax. Celgene was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ.
pagehit

Add or Edit Instrument

Celgene Chart - 1 Year - NAS
  • Intraday
  • 1w
  • 3 Mo.
  • 1y
  • 3y
  • 5y
  • Max
  • Exchange: NAS
  • Chart Options

Estimates for Celgene

2016 2017e 2018e
Dividend - - -
Dividend Yield in % - - -
P/E Ratio 19.73 15.25 12.58
EPS 5.94 7.22 8.75

Celgene Key Figures

Market Cap (USD) 91.31 B
Free Float in % 99.75
Number of Shares (Mio.) 777.97
Cash Flow per Share 3.84
Book Value per Share 8.01
60-Days Volatility 27.27
P/B Ratio 14.63

Base Data Celgene

Symbol CELG
ISIN US1510201049
Indices BX Swiss - USA, S&P 500, NASDAQ 100

About the Company Celgene

Country USA

Celgene Historical Prices

02/23/2017
02/23/2017 06:00:00 PM UTC-0500
118.23 1,538,666
02/22/2017
02/22/2017 06:00:00 PM UTC-0500
119.46 1,703,550
02/21/2017
02/21/2017 06:00:00 PM UTC-0500
119.27 1,321,121
02/20/2017
02/20/2017 06:00:00 PM UTC-0500
119.44 1,692,851
02/16/2017
02/16/2017 06:00:00 PM UTC-0500
121.16 2,007,745

Celgene Peer Group

Abbott Laboratories 45.68
0.6%
AstraZeneca 46.16
0.3%
Bayer 104.55
-0.4%
Bristol-Myers Squibb 56.44
1.2%
Celgene 118.23
-1.0%
GlaxoSmithKline 16.42
0.6%
Johnson & Johnson 122.73
0.8%
Merck 66.16
0.5%
Novartis 77.45
-0.3%
Pfizer 34.26
0.6%

Similar shares with higher 1-year perf.